Regulatory effects of autocrine or paracrine factors on proliferation of glioma cells
Niu Wanxiang, Niu Chaoshi.
Department of Neurosurgery, the Provincial Hospital Affiliated to Anhui Medical University, Anhui Province Key Laboratory of Brain Function and Brain Disease, Anhui Provincial Stereotactic Neurosurgical Institute, Hefei 230001, China
Abstract：Objective To explore the regulatory effects of various types of autocrine or paracrine factors under glioma microenvironment on proliferation of glioma cells.Methods Key words including “glioma”“autocrine or”“ paracrine”“proliferation” were searched in PubMed, CNKI and GOOGLE SCHOLAR databases between January 2004 and May 2016,and relevant recent literatures which related with autocrine or paracrine factors and proliferation of glioma cells were reviewed.Results Multiple factors including growth factors, cytokines, chemokines, nonpeptide factors and steroid hormones participate in the autocrine or paracrine regulatory loop to play effects on proliferation, invasion, diffusion of glioma cells.Conclusions Studies on the mechanisms of autocrine or paracrine in glioma microenvironment may provide further insight into the underlying pathogenesis and may provide new potential targets for diagnosis and treatment.
牛万祥, 牛朝诗. 胶质瘤细胞的自分泌或旁分泌因子对肿瘤增殖的调控作用[J]. 中华解剖与临床杂志, 2017, 22(4): 337-340.
Niu Wanxiang, Niu Chaoshi.. Regulatory effects of autocrine or paracrine factors on proliferation of glioma cells. Chinese Journal of Anatomy and Clinics, 2017, 22(4): 337-340.
Hattermann K, Mentlein R. Glioma cell biology[M]. Berlin: Springer-Verlag, 2014:153-185.
[2]
Mentlein R, Hattermann K, Held-Feindt J. Lost in disruption: role of proteases in glioma invasion and progression[J]. Biochim Biophys Acta, 2012, 1825(2): 178-185. DOI:10.1016/j.bbcan.2011.12.001.
Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment[J]. J Natl Cancer Inst, 2007, 99(21): 1583-1593. DOI:10.1093/jnci/djm187.
[5]
Erdem-Eraslan L, Gao Y, Kloosterhof NK, et al. Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation[J]. Eur J Cancer, 2015, 51(7): 893-903. DOI:10.1016/j.ejca.2015.02.006.
[6]
Auf G, Jabouille A, Delugin M, et al. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor[J]. BMC Cancer, 2013, 13: 597. DOI:10.1186/1471-2407-13-597.
[7]
Nazarenko I, Hede SM, He X, et al. PDGF and PDGF receptors in glioma[J]. Ups J Med Sci, 2012, 117(2): 99-112. DOI:10.3109/03009734.2012.665097.
[8]
Assanah M, Lochhead R, Ogden A, et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses[J]. J Neurosci, 2006, 26(25): 6781-6790. DOI:10.1523/JNEUROSCI.0514-06.2006.
[9]
Awad AJ, Burns TC, Zhang Y, et al. Targeting MET for glioma therapy[J]. Neurosurg Focus, 2014, 37(6): E10. DOI:10.3171/2014.9.FOCUS14520.
[10]
Zhang L, Virani S, Zhang Y, et al. Molecular imaging of c-Met tyrosine kinase activity[J]. Anal Biochem, 2011, 412(1): 1-8. DOI:10.1016/j.ab.2011.01.028.
[11]
Johnson J, Ascierto ML, Mittal S, et al. Genomic profiling of a hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma[J]. J Transl Med, 2015, 13: 306. DOI:10.1186/s12967-015-0667-x.
[12]
Ulbricht U, Eckerich C, Fillbrandt R, et al. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo[J]. J Neurochem, 2006, 98(5): 1497-1506. DOI:10.1111/j.1471-4159.2006.04022.x.
[13]
Stylianou DC, Auf der Maur A, Kodack DP, et al. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor[J]. Oncogene, 2009, 28(37): 3296-3306. DOI:10.1038/onc.2009.184.
[14]
Ma J, Lang B, Wang X, et al. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma[J]. J Clin Neurosci, 2014, 21(11): 1885-1890. DOI:10.1016/j.jocn.2014.02.020.
[15]
Qu DW, Liu Y, Wang L, et al. Glial cell line-derived neurotrophic factor promotes proliferation of neuroglioma cells by up-regulation of cyclins PCNA and Ki-67[J]. Eur Rev Med Pharmacol Sci, 2015, 19(11): 2070-2075.
[16]
Ng WH, Wan GQ, Peng ZN, et al. Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas[J]. J Clin Neurosci, 2009, 16(3): 427-436. DOI:10.1016/j.jocn.2008.06.002.
[17]
Zhu VF, Yang J, Lebrun DG, et al. Understanding the role of cytokines in glioblastoma multiforme pathogenesis[J]. Cancer Lett, 2012, 316(2): 139-150. DOI:10.1016/j.canlet.2011.11.001.
[18]
Wang H, Lathia JD, Wu Q, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth[J]. Stem Cells, 2009, 27(10): 2393-2404. DOI:10.1002/stem.188.
[19]
Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway[J]. Proc Natl Acad Sci USA, 2004, 101(52): 18117-18122. DOI:10.1073/pnas.0408258102.
[20]
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer[J]. Clin Cancer Res, 2010, 16(11): 2927-2931. DOI:10.1158/1078-0432.CCR-09-2329.
[21]
Uemae Y, Ishikawa E, Osuka S, et al. CXCL12 secreted from glioma stem cells regulates their proliferation[J]. J Neurooncol, 2014, 117(1): 43-51. DOI:10.1007/s11060-014-1364-y.
[22]
Zhang J, Sarkar S, Cua R, et al. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis[J]. Carcinogenesis, 2012, 33(2): 312-319. DOI:10.1093/carcin/bgr289.
[23]
Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling[J]. Annu Rev Biochem, 2009, 78: 743-768. DOI:10.1146/annurev.biochem.78.072407.103733.
[24]
Marfia G, Campanella R, Navone SE, et al. Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells[J]. Glia, 2014, 62(12): 1968-1981. DOI:10.1002/glia.22718.
[25]
Li W, Graeber MB. The molecular profile of microglia under the influence of glioma[J]. Neuro-oncology, 2012, 14(8): 958-978. DOI:10.1093/neuonc/nos116.
[26]
Gomes RN, Colquhoun A. E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro[J]. Lipids Health Dis, 2012, 11: 171. DOI:10.1186/1476-511X-11-171.
[27]
Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma?[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(10): 2421-2427. DOI:10.1158/1055-9965.EPI-10-0658.
Dueas Jiménez JM, Candanedo Arellano A, Santerre A, et al. Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas[J]. J Neurooncol, 2014, 119(2): 275-284. DOI:10.1007/s11060-014-1509-z.
[31]
González-Arenas A, Valadez-Cosmes P, Jiménez-Arellano C, et al. Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway[J]. J Steroid Biochem Mol Biol, 2014, 144 Pt B: 463-470. DOI:10.1016/j.jsbmb.2014.09.007.
[32]
Atif F, Yousuf S, Stein DG. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling[J]. J Steroid Biochem Mol Biol, 2015, 146: 62-73. DOI:10.1016/j.jsbmb.2014.04.007.
2017, Vol. 22 
